Nov 20, 2025 8:00am EST Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Nov 17, 2025 8:05am EST Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
March 3, 2025 Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
December 20, 2023 Navigating the Future of Pain Management: Ensysce Biosciences’ Innovative Approach